Day: November 2, 2023

Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical pharmacology solutions and capacity, which are now fully available for customers. The expansion includes a 100,000 square feet state-of-the-art facility in Leeds, U.K. as well as approximately 20,000 square feet of new or renovated space, adding capacity and capabilities across its clinical research units (CRUs) in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin.

“The increasing complexity of clinical pharmacology studies demands fit-for-purpose infrastructure, experience and expertise to protect the safety of study participants and the integrity of critically important data,” said Oren Cohen, M.D., Fortrea’s president of Clinical Pharmacology and chief medical officer. “Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists. The investments we have made target the capabilities and capacity that customers need to accurately assess early pipeline candidates and speed those with promise to later-phase development and ultimately to patients who need them.”

Facility enhancements following the completed expansion include Fortrea’s new CRU in Leeds as well as purpose-built rooms in Madison and Daytona designed for flexibility in executing complex early phase clinical studies. Improvements in recreational, living and “work-from-home” spaces at Fortrea CRUs have been constructed to enhance the experience of volunteers participating in research at the sites.

The expansion of Fortrea’s early clinical development pharmacy services facilities includes new state-of-the-art cGMP pharmacies in the Leeds and Daytona CRUs. All Fortrea CRUs will now have cGMP pharmacies within them. This enables on-site manufacture of sterile and non-sterile drug product. The design of its GMP-compliant facilities provides safe handling and delivery of GMP-quality drug product for the unique demands of clinical pharmacology studies, focusing on efficiency and flexibility with the level of controls expected by regulatory authorities and sponsors.

Enhancements in science and technology include the addition of artificial intelligence-enabled programs that optimize bed space utilization and clinic scheduling, and the application of failure modes and effects analysis to de-risk study execution before a study begins. Following investments in data collection systems, all clinical pharmacology study data collected within Fortrea’s CRUs are input directly into a digital bedside data capture system, which can also be used as an efficient electronic data capture solution.

“I believe Fortrea’s early clinical development solutions set a new standard for what the research industry should expect from its partners,” said Dr. Cohen. “I’m so proud of this team and know they will also benefit from the changes we have made. Just as they are inspired by our mission of bringing life-changing treatments to patients faster, I’m inspired by their dedication each day as we deliver solutions to our customers.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements in this press release, particularly those relating to the anticipated financial and other benefits, including, but not limited to, whether the investments at clinical research units in U.S. and U.K. will add capacity, improve therapeutic capabilities, enhance experience for study volunteers, speed development to later-phase trials and improve the integrity of data and whether the addition of artificial intelligence-enabled programs will optimize bed space utilization and clinic scheduling, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from expectations expressed or implied in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in Fortrea’s registration statement on Form 10 initially filed with the SEC on May 15, 2023 (as amended and further supplemented), Fortrea’s quarterly report on Form 10-Q filed with the SEC on August 14, 2023, and in Fortrea’s other filings with the SEC. These forward-looking statements are based on management’s current expectations and are subject to certain risks, uncertainty and changes in circumstances. Fortrea does not undertake responsibility for updating these statements, and these statement speak only as of the date of this press release.

Fortrea Contacts:

Fortrea Media: Sue Zaranek – 919-943-5422, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
Fortrea Investors: Hima Inguva – 877-495-0816, hima.inguva@fortrea.com

GlobeNewswire Distribution ID 8971131

Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.

Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed a multi-year effort to expand its clinical pharmacology solutions and capacity, which are now fully available for customers. The expansion includes a 100,000 square feet state-of-the-art facility in Leeds, U.K. as well as approximately 20,000 square feet of new or renovated space, adding capacity and capabilities across its clinical research units (CRUs) in Dallas, Texas; Daytona, Florida; and Madison, Wisconsin.

“The increasing complexity of clinical pharmacology studies demands fit-for-purpose infrastructure, experience and expertise to protect the safety of study participants and the integrity of critically important data,” said Oren Cohen, M.D., Fortrea’s president of Clinical Pharmacology and chief medical officer. “Our integrated platform of services includes best-in-class infrastructure and experienced professionals who are fully dedicated to clinical pharmacology, including physicians, nurses, clinical scientists, CRAs and pharmacokineticists. The investments we have made target the capabilities and capacity that customers need to accurately assess early pipeline candidates and speed those with promise to later-phase development and ultimately to patients who need them.”

Facility enhancements following the completed expansion include Fortrea’s new CRU in Leeds as well as purpose-built rooms in Madison and Daytona designed for flexibility in executing complex early phase clinical studies. Improvements in recreational, living and “work-from-home” spaces at Fortrea CRUs have been constructed to enhance the experience of volunteers participating in research at the sites.

The expansion of Fortrea’s early clinical development pharmacy services facilities includes new state-of-the-art cGMP pharmacies in the Leeds and Daytona CRUs. All Fortrea CRUs will now have cGMP pharmacies within them. This enables on-site manufacture of sterile and non-sterile drug product. The design of its GMP-compliant facilities provides safe handling and delivery of GMP-quality drug product for the unique demands of clinical pharmacology studies, focusing on efficiency and flexibility with the level of controls expected by regulatory authorities and sponsors.

Enhancements in science and technology include the addition of artificial intelligence-enabled programs that optimize bed space utilization and clinic scheduling, and the application of failure modes and effects analysis to de-risk study execution before a study begins. Following investments in data collection systems, all clinical pharmacology study data collected within Fortrea’s CRUs are input directly into a digital bedside data capture system, which can also be used as an efficient electronic data capture solution.

“I believe Fortrea’s early clinical development solutions set a new standard for what the research industry should expect from its partners,” said Dr. Cohen. “I’m so proud of this team and know they will also benefit from the changes we have made. Just as they are inspired by our mission of bringing life-changing treatments to patients faster, I’m inspired by their dedication each day as we deliver solutions to our customers.”

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements in this press release, particularly those relating to the anticipated financial and other benefits, including, but not limited to, whether the investments at clinical research units in U.S. and U.K. will add capacity, improve therapeutic capabilities, enhance experience for study volunteers, speed development to later-phase trials and improve the integrity of data and whether the addition of artificial intelligence-enabled programs will optimize bed space utilization and clinic scheduling, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from expectations expressed or implied in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in Fortrea’s registration statement on Form 10 initially filed with the SEC on May 15, 2023 (as amended and further supplemented), Fortrea’s quarterly report on Form 10-Q filed with the SEC on August 14, 2023, and in Fortrea’s other filings with the SEC. These forward-looking statements are based on management’s current expectations and are subject to certain risks, uncertainty and changes in circumstances. Fortrea does not undertake responsibility for updating these statements, and these statement speak only as of the date of this press release.

Fortrea Contacts:

Fortrea Media: Sue Zaranek – 919-943-5422, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
Fortrea Investors: Hima Inguva – 877-495-0816, hima.inguva@fortrea.com

LeddarTech Anuncia sua Participação em Conferências do Quarto Trimestre de 2023 com o Investidor

QUEBEC CITY, Canadá, Nov. 01, 2023 (GLOBE NEWSWIRE) — A LeddarTech®, uma empresa de software automotivo que fornece tecnologia patenteada de software de fusão e percepção de sensores de baixo nível para ADAS e AD, anuncia a participação de Frantz Saintellemy, Presidente e CEO, nos seguintes eventos com investidores:

A LeddarTech participará de reuniões e de bate-papos informais com potenciais investidores e analistas do setor. Para mais informação ou para se inscrever, visite a seção “Events & Presentations” de relações com o Investidor da LeddarTech.

No dia 13 de junho de 2023, a Prospector Capital Corp. (“Prospector”) (NASDAQ: PRSR, PRSRU, PRSRW), uma empresa com isenção das Ilhas Caimã liderada pelo ex-Presidente da Qualcomm, Derek Aberle, e presidida pelo ex-Vice-Presidente da Qualcomm, Steve Altman, entraram em um acordo definitivo de fusão da empresa com a LeddarTech. Após a conclusão da transação, prevista para o quarto trimestre de 2023, a nova empresa conjunta, LeddarTech Holdings Inc. (“Newco”), deverá ser listada na NASDAQ sob o símbolo “LDTC”.

Sobre a LeddarTech

Uma empresa global de software fundada em 2007 e sediada na cidade de Quebec, com centros adicionais de P&D em Montreal, Toronto e Tel Aviv, Israel, a LeddarTech desenvolve e fornece soluções abrangentes de software de percepção que permitem a implantação de aplicações ADAS e de condução autônoma (AD). O software de nível automotivo da LeddarTech aplica algoritmos avançados de IA e visão computacional para gerar modelos 3D precisos do ambiente, permitindo uma melhor tomada de decisão e navegação mais segura. Esta tecnologia de alto desempenho, escalonável e econômica é disponível para OEMs e fornecedores de Nível 1-2 para a implementação eficiente de soluções ADAS para veículos automotivos e off-road.

A LeddarTech é responsável por várias inovações de sensor remoto, com mais de 150 patentes solicitadas (80 concedidas) que aprimoram os recursos de ADAS e AD. A percepção de veículos é fundamental para tornar a mobilidade global mais segura, eficiente, sustentável e acessível: e é por isso que a LeddarTech deseja se tornar a solução de software de fusão e percepção de sensores mais amplamente adotada.

Para mais informação sobre a LeddarTech, visite www.LeddarTech.com, LinkedIn, Twitter (X), Facebook e YouTube.

Sobre a Prospector Capital Corp.

A Prospector é uma empresa de aquisição com finalidade especial criada com a finalidade de realizar fusão, troca de ações, aquisição de ativos, compra de ações, reorganização ou fusão de empresas semelhante com uma ou mais empresas, com foco em empresas com soluções avançadas e altamente diferenciadas para o setor de tecnologia. A empresa é liderada por uma equipe de investidores e executivos experientes focados em identificar e investir em empresas de alto crescimento, com equipes de gerenciamento fortes e oportunidades de mercado atraentes. Os títulos da Prospector são negociados na NASDAQ sob os símbolos “PRSR”, “PRSRU” e “PRSRW”.

Informações Importantes Sobre a Transação Proposta e Onde Encontrá-la

Em conexão com a proposta fusão das empresas, a Prospector, a LeddarTech e a Newco irão preparar e protocolar a Declaração de Registro na SEC no Formulário F-4 (a “Declaração de Registro”), e a Prospector irá enviar as procurações/prospecto da Declaração de Registro para seus acionistas e protocolar outros documentos sobre a fusão da empresa na SEC. Este comunicado à imprensa não substitui nenhuma procuração, declaração de registro, declaração/prospecto de procuração ou outros documentos que a Prospector ou a Newco possam protocolar na SEC em conexão com a fusão das empresas. OS INVESTIDORES E DETENTORES DE VALORES MOBILIÁRIOS DEVEM LER ATENTAMENTE E NA ÍNTEGRA A DECLARAÇÃO DE REGISTRO QUANDO DISPONÍVEL, QUAISQUER ALTERAÇÕES OU SUPLEMENTOS À DECLARAÇÃO DE REGISTRO E OUTROS DOCUMENTOS PROTOCOLADOS PELO PROSPECTOR OU PELA NEWCO NA SEC EM CONEXÃO COM A FUSÃO DA EMPRESA PORQUE ESSES DOCUMENTOS CONTERÃO INFORMAÇÕES IMPORTANTES. Investidores e detentores de valores mobiliários poderão obter cópias gratuitas da Declaração de Registro e outros documentos protocolados na SEC pela Prospector ou pela Newco no website da SEC em www.sec.gov.

Declarações de Previsão

Certas declarações contidas neste comunicado de imprensa podem ser consideradas declarações de previsão na acepção da Lei de Reforma de Litígios de Títulos Privados dos EUA de 1995, Seção 27A da Lei de Títulos e Valores Mobiliários e Seção 21E da Lei de Câmbio (cujas declarações de previsão também devem incluir declarações de previsão e informações de previsão na acepção das leis de valores mobiliários canadenses aplicáveis), incluindo, mas não se limitando a, declarações sobre a fusão de empresas envolvendo a Prospector, a LeddarTech e a Newco, a capacidade de concluir a fusão das empresas e a sua ocasião, os benefícios previstos da fusão das empresas, o fechamento do financiamento de colocação privada, as receitas e declarações previstas relacionadas à estratégia antecipada da Newco, operações futuras, perspectivas, objetivos e projeções financeiras e outras métricas financeiras. As declarações de previsão geralmente incluem declarações de natureza preditiva e dependem ou se referem a eventos ou condições futuras, e incluem palavras como “pode”, “irá”, “deveria”, “esperaria”, “antecipa”, “planeja”, “provável”, “acredita”, “estima”, “projeta”, “pretende e outras expressões semelhantes, entre outras. Declarações que não sejam de fatos históricos são declarações de previsão. Declarações de previsão tomam por base convicções e suposições atuais sujeitas a riscos e incertezas e não são garantias de desempenho futuro. Os resultados reais podem ser substancialmente diferentes dos resultados contidos em qualquer declaração de previsão devido a vários fatores, incluindo, sem limitação: (i) o risco de que as condições para o fechamento da fusão das empresas não sejam satisfeitas, incluindo a falha em obter a aprovação dos acionistas em tempo hábil ou obter a aprovação dos acionistas para a fusão das empresas ou a falha em obter quaisquer autorizações regulatórias necessárias e em tempo hábil, incluindo do Superior Tribunal de Justiça do Quebec; (ii) incertezas quanto ao momento da consumação da fusão das empresas e a capacidade da Prospector, da LeddarTech e da Newco de concluir a fusão das empresas; (iii) a possibilidade de que outros benefícios antecipados da fusão das empresas não sejam realizados e o tratamento fiscal antecipado da fusão das empresas; (iv) a ocorrência de qualquer evento que possa dar origem à rescisão da fusão das empresas; (v) o risco de que o litígio dos acionistas em conexão com a fusão das empresas ou outros acordos ou investigações possa afetar o momento ou a ocorrência da fusão das empresas ou resultar em custos significativos de defesa, indenização e responsabilidade; (vi) mudanças gerais na economia e/ou condições específicas do setor; (vii) possíveis interrupções da fusão das empresas que poderiam prejudicar os negócios da LeddarTech; (viii) a capacidade da LeddarTech de reter, atrair e contratar pessoal-chave; (ix) possíveis reações adversas ou mudanças nas relações com clientes, funcionários, fornecedores ou outras partes resultantes do anúncio ou conclusão da fusão das empresas; (x) potencial incerteza nos negócios, incluindo mudanças nas relações comerciais existentes durante a pendência da fusão das empresas que possam afetar o desempenho financeiro da LeddarTech; (xi) desenvolvimentos legislativos, regulatórios e econômicos; (xii) imprevisibilidade e gravidade de eventos catastróficos, incluindo, mas não se limitando a, atos de terrorismo, eclosão de guerra ou hostilidades, e qualquer epidemia, pandemia ou surto de doença (incluindo COVID-19), bem como a resposta da administração a qualquer um dos fatores mencionados acima; (xiii) acesso a capital e financiamentos e a capacidade da LeddarTech estar em conformidade com os acordos de dívidas; e (xiv) outros fatores de risco, detalhados ocasionalmente nos relatórios da Prospector protocolados na SEC, incluindo o Relatório Anual da Prospector no Formulário 10-K, Relatórios Trimestrais periódicos no Formulário 10-Q, Relatórios Atuais periódicos no Formulário 8-K e outros documentos protocolados na SEC, bem como os fatores de risco mencionados da Declaração de Registro. A lista anterior de fatores importantes não é exaustiva. Nem a Prospector nem a LeddarTech podem dar qualquer garantia de que as condições para a fusão das empresas serão satisfeitas. Exceto conforme exigido pela lei aplicável, nem a Prospector nem a LeddarTech assumem qualquer obrigação de revisar ou atualizar qualquer declaração de previsão, ou de fazer quaisquer outras declarações de previsão, seja como resultado de novas informações, eventos futuros ou de outra forma.

Sem Oferta ou Solicitação

Este comunicado à imprensa não constitui uma oferta de venda nem uma solicitação de uma oferta de compra de qualquer título mobiliário da Prospector ou da Newco, uma solicitação de qualquer voto ou aprovação, nem deverá haver qualquer venda desses valores mobiliários em qualquer estado ou outra jurisdição onde tal oferta, venda ou solicitação seja ilegal antes do registro ou qualificação sob as leis de valores mobiliários de qualquer estado ou jurisdição. Nenhuma oferta de valores mobiliários será feita, exceto por meio de um prospecto que atenda aos requisitos da Seção 10 da Lei de Valores Mobiliários de 1933, alterada (Lei de Valores Mobiliários).

Participantes da Solicitação

A Prospector, a LeddarTech, a Newco, e alguns dos seus respectivos diretores, executivos e funcionários, podem ser considerados participantes da solicitação de procurações em conexão com a fusão das empresas. Informações sobre os diretores e diretores executivos da Prospector podem ser encontradas no Relatório Anual no Formulário 10-K do exercício fiscal encerrado em 31 de dezembro de 2022, protocolado na SEC em 31 de março de 2023. As informações sobre as pessoas que podem, de acordo com as regras da SEC, ser consideradas participantes na solicitação de procurações em conexão com a fusão das empresas, incluindo uma descrição dos seus interesses diretos ou indiretos, por participações em títulos ou de outra forma, serão incluídas na Declaração de Registro e outros materiais relevantes quando protocolados na SEC. Esses documentos podem ser obtidos gratuitamente na fonte indicada acima.

Contato:
Daniel Aitken, Vice-Presidente, Marketing Global, Comunicações e Relacionamento com o Investidor, LeddarTech Inc. Tel.: + 1-418-653-9000 ramal 232 daniel.aitken@LeddarTech.com

Os logotipos Leddar, LeddarTech, LeddarVision, LeddarSP, VAYADrive, VayaVision e afins são marcas comerciais ou marcas comerciais registradas da LeddarTech Inc. e suas subsidiárias. Todas as outras marcas e nomes de produtos são ou podem ser marcas comerciais ou marcas comerciais registradas usadas para identificar produtos ou serviços de seus respectivos proprietários.

GlobeNewswire Distribution ID 8970829

Accra Lions tame Heart of Lions to move out of relegation zone

The clash of the two lions resulted in a victory for Accra Lions, who edged Kpando Heart of Lions 2-1 in a matchday eight encounter played at the Accra Sports Stadium. Two first-half goals from Daniel Kwame Awuni and Ali Mohammed secured three points for Accra Lions as they handed Heart of Lions their first defeat of the season. The three points for Accra Lions see them move out of the relegation zone to 14th on the league table, while Hearts of Lions are rock bottom with six points. The game started on a blistering note with Accra Lions controlling affairs and deservedly taking the lead after a horrendous mistake by Heart of Lions goalkeeper Osae gifting Ali Mohammed a tape in from close range. Matters got worse for the away side as Awuni finished off a brilliant team move in the late stages of the first half. Heart of Lions started the second half with intensity as they looked to pull one back, keeping Accra Lions largely on the back foot. They did pull one back in the 77th minute through Christopher Agyeman Boateng, but it only served as consolation as Accra Lions held on to their lead to record all three points.

Source: Ghana News Agency

Ghana, Danish company to explore opportunities of assembling electric vehicles

The Ministry of Trade and Industry has signed a non-binding Memorandum of Understanding with a Danish private limited company, Byteblocs International, to explore the opportunity of assembling electric vehicles in Ghana. The agreement include the investment and development of an Aluminum Recycling and Components Manufacturing Plant, which will include Lithium batteries and LED Lighting. The signing ceremony took place when Ghana’s Ambassador to Denmark, Madam Sylvia Annoh, led a Danish business delegation to pay a courtesy call on the Minister of Trade and Industry, Mr. Kobina Tahir Hammond. Mr Hammond initialed for the Ministry, whilst Jakob Munkgaard Andersen signed on behalf of Byteblocs. The Parties agreed that the implementation of the Project contemplated by the agreement would be subject to the receipt of all applicable governmental, regulatory, and other approvals that may be required as per the laws and regulations of the respective countries of each Party and each Party’s internal regulations, including, but not limited to Standards and Certification. As part of its responsibilities under the MoU, the Byteblocs will take into consideration sustainable and environmentally friendly production systems, skills development, and the transfer of technology to Ghanaians, including partnerships with local suppliers and distributors and training for employees and agents. The project will also include the setting up aftersales stations or centres across the country. On its part, the Ministry of Trade and Industry and its agencies and relevant authorities, will assist the Project in identifying suitable land for acquisition, as well as offer relevant incentives and regulatory support to the Project in line with the relevant policies and laws of Ghana. The Ministry will also assist the Company to acquire residence and working permits in Ghana, including visas for planning and commencement activities. The MoU will remain in effect for a period of five years, even though either Party may terminate it at any time by giving the other Party thirty (30) days’ written notice.

Source: Ghana News Agency

Stop putting mobile phones around the breast, it is very risky – Midwife

A Mid-wife at the Dormaa Presbyterian Hospital, Madam Regina Amponsah, has advised women to stop putting mobile phones around their breast because that could contribute to breast cancer. She said the habit was very risky because the vibration from the phone could heat up the breast area and prolonged heating may result in breast cancer. Madam Amposah made this known in an interview with the Ghana News Agency at the Dormaa Ahenkro in the Bono Region, after an event to climax the Breast Cancer Awareness Month of October at the hospital. The event was organised by the hospital in collaboration with the George Gyewu Family Foundation, to sensitise the public on breast cancer, screening, and examination service. She said the excessive intake of alcohol, smoking, obesity, and anti-ageing pills that contained hormones, particularly for women, were some other dangerous factors that could cause breast cancer. Madam Amponsah observed that the lack of a Mammogram at the hospital was making it stressful for women who were to be screened in the area for suspected cases of the disease,?since they must be referred to as far as the Regional Hospital in Sunyani, for accurate detection, confirmation, and diagnosis. She made a passionate appeal to individuals and Non-Governmental Organisations (NGOs) to help the hospital acquire a mammogram to be able to render quality services to people in the area. Madam Amponsah stressed that the hospital was extending breast cancer education at churches, durbars, local radio stations and one-to-one education to strengthen the spread of the information to the public to help reduce the number of breast cancer cases. She declared that the feeling of hardened lump, blood fluid, and rashes at the breast and at the nipples were some of the signs and symptoms of the disease and advised women to report immediately to the hospital for appropriate medical care and early treatment.

Source: Ghana News Agency

Medeama Coach describes defeat to Hearts as a ‘painful one’.

Augustine Evans Adotey Head Coach of Medeama SC has described their 3-1 loss to Accra Hearts of Oak in the eighth week of betPawa Ghana Premier League as a ‘painful defeat’. In a post-match interview, he said, ‘The outcome of today’s game is one of the things painful things that happened to the entire team. ‘But we take the defeat in our strides and hope to turn things around in the subsequent games,’ he noted. He, however, noted that Heart was the better side and, hence deserved to win the game. ‘Hearts played very well today, they did very well and took their chances early and won the game so let’s give credit to them,’ he noted. The coach said Hearts were determined to win the game, to move out of the relegation zone hence their output. Medeama, the current league champions and Ghana’s campaigners in the CAF Champions League, have not had a smooth run in the league since it started. However, the performance at the continental level seems to have been impressive, with a first-time entry into the CAF Champions League.

Source: Ghana News Agency

Trader in court for allegedly stealing GHC80,000

A 57-year-old trader has appeared before an Accra Circuit Court for allegedly misappropriating GHC80,000 belonging to a businesswoman. Eric Annan is reported to have persuaded the complainant that the wood product business was profitable, and as a result, the complainant took out a GHC80,000 loan and gave it to the accused. Annan, who led the complainant’s son to pay for a quantity of wood, then returned and collected the wood without his (complainant’s son’s) knowledge and went into hiding. He pleaded not guilty to the charge of stealing, The court presided over by Mrs. Evelyn Asamoah admitted Annan to bail in the sum of GHC100,000 with two sureties. The prosecution was ordered to file their disclosures and the matter was adjourned to November 22, 2023. Inspector Chief Inspector Clemence Takyi said the complainant, Mavis Asante is a businesswoman residing at Weija, Accra. Annan resides in Odorkor Official Town. The prosecution said the complainant has a provision shop at Odorkor and Annan was her customer. The two later became friends. The prosecutor told the court that during one of his visits to the complainant, Annan suggested she augment her provision selling with the wood business, claiming it was profitable. According to the prosecution, Annan further explained that he purchased timber from the Western North region and transported it to Accra for sale. It said the complainant told Annan that she was a woman and could not be travelling about as such and that he should ‘teach’ her son the business. Chief Inspector Takyi said Annan agreed and told the complainant that if they had GHC80,000, they could start the business and he (Annan) would find them a customer. The prosecution said the complainant obtained a loan of GHC80,000 and gave it to Annan to accompany her son to purchase the wood. On June 28, 2023, Annan went to the sawmill and ordered wood worth GHC68,000, paid a deposit of GHC50,000 and stated that he would pay the balance of GHC18,000 after he collected the wood. The prosecution said Annan kept GHC12,000 for himself. The prosecutor said the sawmill cashier told Annan that the wood would be ready in a fourth night. According to the prosecutor, Annan refused to answer the complainant’s son’s calls, so he went to the sawmill in Sefwi Wiawso and was told that Annan had come for the wood. The prosecution stated that all efforts to reach Annan proved futile, so the complainant reported the matter to the police, and he was arrested with the assistance of Sefwi Wiawso Police. The prosecutor said Annan admitted going for the wood, selling it, and using the proceeds. Annan promised to refund the money and subsequently returned GHC14,046.

Source: Ghana News Agency

Renovation: Wike promises timely completion of National Mosque, Christian Centre

Mr Nyesom Wike, Minister of the Federal Capital Territory (FCT), has promised to ensure timely completion of ongoing renovation of the National Mosque and the National Christian Centre, Abuja.

Wike gave the assurance after he inspected the ongoing renovation of the two national monuments in Abuja on Thursday.

The News Agency of Nigeria (NAN) recalls that the leadership of the National Mosque and the Christian Worship Centre had visited Wike and appealed for the completion of renovation projects.

Wike, after assuring them of his full support, promised to visit the two centres to see things for himself before deciding on the next line of action.

The minister told journalists shortly after the inspection tour that the renovation at the National Mosque stopped due to additional work that ought to be done.

He expressed satisfaction with what was done so far and gave the approval for funds to be released to the contractor to enable him to complete the additional work.

On the National Christian Centre, Wike said he would look at the cost of the phase two renovation project and approve it if it is within what FCT can fund.

He said that if the cost exceeds FCT approval threshold, he would approach President Bola Tinubu for approval, assuring that Tinubu would not abandon such important national monuments.

“He is not anti any religion; he takes all religion as one, because we are one Nigeria,” he said.

Source: News Agency of Nigeria

Rivers crisis: Those accusing me of demanding 25% are ignorant – Wike

The Minister of the Federal Capital Territory Administration (FCT), Mr Nyesom Wike, said on Thursday, that those accusing him of demanding 25 per cent from Rivers government were ignorant.

Wike stated this when a delegation of Rivers Caucus in the 10th National Assembly comprising three Senators and 11 members of the House of Representatives visited him in Abuja.

The News Agency of Nigeria (NAN) reports that a crisis had erupted in Rivers, after an attempt by the Rivers Assembly to impeach the incumbent Governor, Mr Siminalayi Fubara.

‘I was a governor for eight years. I am now FCT Minister, and some will say that I am asking for 25 per cent. That is madness.

“I am not interested in the governance of Rivers; I am not interested. I am here as a governor in FCT, but I am interested in the political structure of Rivers which we have built over the years.

“If anybody dares to bring it down, the person will face the crisis he wants in his life. Perform or don’t perform, but don’t touch our political structure.

“Anybody who puts his hand in our structure, anything you see, take it”, he warned.

He urged members of the caucus not to disappoint the state but work as a team for the good of the people of Rivers.

The Minister said: “When you make mistakes, we will call you and tell you that you are making a mistake. Take it in good faith that we are calling your attention because we think that you are derailing.

“But when we call you don’t say we are expecting a kickback of 25 per cent from you or so and so per cent.

“All of us are one. We’ve built this political structure for a long time, since 2015, and we have emerged victorious.

“As the opposition party from 2015, I saw hell. The Federal Government fought me left right and centre, but with your support, we survived.

“When you work as a team, you’ll discover that it is difficult for an outsider to defeat you at home.”

Earlier, Mr Kinsley Chinda (PDP-Rivers), Minority Leader in the House of Representatives, who spoke on behalf of the delegation, said that the visit was to identify with the minister.

Chinda, representing Obio/Akpor Federal Constituency, added that the visit was also to thank Wike for his support during the 2023 general elections.

He added that he played a key role in their emergence as law makers in the National Assembly.

He said that Wike’s appointment was well deserved, condemned the political crisis in the state and declared their total support to Wike.

Source: News Agency of Nigeria